{"id":"NCT00550407","sponsor":"GlaxoSmithKline","briefTitle":"An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients","officialTitle":"Study SCA104779, an Evaluation of BW430C (Lamotrigine) Versus Placebo in the Prevention of Mood Episodes in Bipolar I Disorder Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2007-10-29","resultsPosted":"2010-07-27","lastUpdate":"2016-11-23"},"enrollment":215,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"lamotrigine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"BW430C(lamotrigine)","type":"ACTIVE_COMPARATOR"}],"summary":"This study is planned to objectively assess the efficacy and safety of lamotrigine maintenance therapy after symptoms of mood episode had been stabilised by open-label treatment with lamotrigine alone or in combination with other psychotropic medication in patients with bipolar I disorder.","primaryOutcome":{"measure":"Time to Withdrawal From Study","timeFrame":"Randomization to Study Withdrawal (up to Week 26)","effectByArm":[{"arm":"Placebo","deltaMin":67.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.010"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":17,"exclusionCount":null},"locations":{"siteCount":60,"countries":["Japan"]},"refs":{"pmids":["34523118"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":215},"commonTop":["Nasopharyngitis","Headache","Nausea","Dizziness","Constipation"]}}